π΅οΈ Dynavax Technologies Corporation ($DVAX)
SEC insider & ownership activity, last 12 months Β· CIK 1029142 Β· every row links its SEC filing
Over the last 12 months insiders sold $2.2M with no open-market buying against it. David Novack sold $2.2M in discretionary trades (DecβJan). One red-flag 8-K in the window: Delisting notice (3.01), Feb 10, 2026.
π¨ 1 signal active β
planned-vs-executed verdicts, pre-event flags, and cluster context live in the
API and the
alerts bot.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
0 buyers, $0 (0 lots) Β· 1 seller, $2.2M (2 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| David Novack | 0 | β | 2 | $2.2M | Jan 15, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| BlackRock, Inc. | 14.2% | 13G | Jul 17, 2025 | filing β | |
| DEEP Track Capital, LP | 13.5% | 13D | Feb 18, 2025 | filing β | |
| DEEP Track Biotechnology Master Fund, Ltd. | 13.5% | 13D | Feb 18, 2025 | filing β | |
| David Kroin | 13.5% | 13D | Feb 18, 2025 | filing β |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| David Novack | $1.8M | Jan 15, 2026 | filing β |
| David Novack | $465K | Dec 24, 2025 | filing β |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Material agreement (1.01) | Feb 10, 2026 | filing β |
| Agreement terminated (1.02) | Feb 10, 2026 | filing β |
| Acquisition or disposition (2.01) | Feb 10, 2026 | filing β |
| Delisting notice (3.01) | Feb 10, 2026 | filing β |
| Material Modifications to Rights of Security Holders (3.03) | Feb 10, 2026 | filing β |
| Change of control (5.01) | Feb 10, 2026 | filing β |
| Officer/director changes (5.02) | Feb 10, 2026 | filing β |
| Charter/bylaw changes (5.03) | Feb 10, 2026 | filing β |
| Financial Statements and Exhibits (9.01) | Feb 10, 2026 | filing β |
| Material agreement (1.01) | Dec 23, 2025 | filing β |
| Officer/director changes (5.02) | Dec 23, 2025 | filing β |
| Reg FD disclosure (7.01) | Dec 23, 2025 | filing β |
| Financial Statements and Exhibits (9.01) | Dec 23, 2025 | filing β |
| Earnings (2.02) | Nov 5, 2025 | filing β |
| Financial Statements and Exhibits (9.01) | Nov 5, 2025 | filing β |
| Officer/director changes (5.02) | Oct 15, 2025 | filing β |